Key result
Growth hormone administration improved fatty liver in a 17-year-old boy with panhypopituitarism, whereas hydrocortisone and levothyroxine treatments did not.
Why the study?
Does growth hormone administration improve fatty liver in a patient with panhypopituitarism?
Does growth hormone administration improve fatty liver in a patient with panhypopituitarism?
Growth hormone administration can improve fatty liver associated with panhypopituitarism, suggesting the condition may be attributable to a growth hormone deficient state.
Hypothesis-generating for GH replacement in fatty liver with panhypopituitarism; prospective studies required before clinical adoption.
A 17 year old boy was admitted because of short stature and hepatomegaly. He was diagnosed with panhypopituitarism and fatty liver. The fatty liver improved, not with hydrocortisone or levothyroxine treatment, but with growth hormone administration. The fatty liver in this patient was attributable to a growth hormone deficient state.
No takes yet. Share an insight, caveat, or question.
Takano et al. (1997) studied this question. Growth hormone administration improved fatty liver in a 17-year-old boy with panhypopituitarism, whereas hydrocortisone and levothyroxine treatments did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: